KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 6037 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials. PMID 36125472 · JAMA · 2022-Sep-20 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
PEDAL protocol: a prospective single-arm paired comparison of multiparametric MRI and 18F-DCPFyl PSMA PET/CT to diagnose prostate cancer. PMID 36123093 · BMJ Open · 2022-Sep-19 This is a phase III clinical trial protocol for a diagnostic imaging study (PSMA PET/CT vs. mpMRI) in prostate cancer. It is a non-randomized, single-arm, paired comparison design without a drug intervention. The primary outcome is diagnostic accuracy (sensitivity, specificity), not a time-to-event efficacy endpoint like OS or PFS. The publication is explicitly a protocol without reported results.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE. PMID 36117201 · NPJ Breast Cancer · 2022-Sep-19 The study is an eligible phase III randomized drug trial in oncology, but the abstract does not establish the presence of a primary/key secondary time-to-event endpoint (KM/HR). It reports an event count for invasive disease-free survival (IDFS) in a subgroup, but without formal time-to-event analysis metrics. Therefore, it does not meet the strict inclusion criterion for time-to-event efficacy.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Management of elderly patients with unresectable pancreatic cancer. PMID 35789391 · Jpn J Clin Oncol · 2022-Sep-18 The record is a review article discussing treatment of elderly patients with pancreatic cancer, referencing phase III trials but not presenting original results from a specific trial. It does not contain a Kaplan-Meier plot, hazard ratio, or any primary time-to-event efficacy endpoint data from a randomized trial.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Inosine Pranobex in COVID-19 Patients: A Multicenter Phase 3 Randomized Double-Blind, Placebo-Controlled Trial. PMID 36246300 · Adv Ther (Weinh) · 2022-Sep-16 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Radical Hysterectomy for Early Stage Cervical Cancer. PMID 36141917 · Int J Environ Res Public Health · 2022-Sep-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Hemopatch to Prevent Lymphatic Leak after Robotic Prostatectomy and Pelvic Lymph Node Dissection: A Randomized Controlled Trial. PMID 36139636 · Cancers (Basel) · 2022-Sep-15 The study is a randomized, phase III trial in oncology (prostate cancer), but the intervention is a medical device (Hemopatch), not a drug, and the primary efficacy endpoint is drain output volume, which is not a time-to-event endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A study protocol for a double-blind randomised placebo-controlled trial evaluating the efficacy of carrageenan nasal and throat spray for COVID-19 prophylaxis-ICE-COVID. PMID 36109791 · Trials · 2022-Sep-15 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months. PMID 36106642 · J Clin Invest · 2022-Sep-15 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Lessons from a large-scale COVID-19 vaccine trial. PMID 36106630 · J Clin Invest · 2022-Sep-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Preoperative hypofractionated radiotherapy for soft tissue sarcomas: a systematic review. PMID 36104789 · Radiat Oncol · 2022-Sep-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial. PMID 36104138 · BMJ Open · 2022-Sep-14 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H S B
严格 v3 独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
How patients with multiple sclerosis acquire disability. PMID 35104840 · Brain · 2022-Sep-14 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Patient Decision Aid (i.ARTs) to Facilitate Women's Choice Between Oral and Long-Acting Injectable Antiretroviral Treatment for HIV: Protocols for its Development and Randomized Controlled Pilot Trial. PMID 36099004 · JMIR Res Protoc · 2022-Sep-13 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Polyhexamethylene biguanide hydrochloride (PHMB)-properties and application of an antiseptic agent. A narrative review. PMID 36083163 · Eur J Ophthalmol · 2022-Sep-09 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibition. PMID 36068332 · NPJ Precis Oncol · 2022-Sep-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Automated digital counselling with social network support as a novel intervention for patients with heart failure: protocol for randomised controlled trial. PMID 36691152 · BMJ Open · 2022-Sep-05 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. PMID 36064592 · Trials · 2022-Sep-05 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Building Emotional Awareness and Mental Health (BEAM): study protocol for a phase III randomized controlled trial of the BEAM app-based program for mothers of children 18-36 months. PMID 36064436 · Trials · 2022-Sep-05 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers. PMID 36077477 · Int J Mol Sci · 2022-Sep-03 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Opening the Conversation: study protocol for a Phase III trial to evaluate a couple-based intervention to reduce reproductive and sexual distress among young adult breast and gynecologic cancer survivor couples. PMID 36056413 · Trials · 2022-Sep-02 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
An Evaluation of a Web-Based Decision Aid for Treatment Planning of Small Kidney Tumors: Pilot Randomized Controlled Trial. PMID 36053558 · JMIR Res Protoc · 2022-Sep-02 The record describes a pilot randomized controlled trial (RCT) evaluating a web-based decision aid for treatment planning of small kidney tumors. While it is oncology-related, human, and randomized, it fails multiple eligibility criteria: it is not a definitive Phase III/IIIb or Phase II/III trial (it is a pilot study), it does not involve a drug-containing intervention (the intervention is a decision aid, not a drug), it lacks a primary or key secondary time-to-event efficacy endpoint (the endpoints are decisional outcomes, not survival or progression metrics), and it is a protocol/report of a planned study rather than an original formal result report with efficacy data.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Hypofractionated versus conventional intensity-modulated radiation irradiation (HARVEST-adjuvant): study protocol for a randomised non-inferior multicentre phase III trial. PMID 36581983 · BMJ Open · 2022-Sep-01 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
One-Year Outcome Trajectories and Factors Associated with Functional Recovery Among Survivors of Intracerebral and Intraventricular Hemorrhage With Initial Severe Disability. PMID 35877105 · JAMA Neurol · 2022-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis. PMID 35877104 · JAMA Neurol · 2022-Sep-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Dose- and Volume-Limiting Late Toxicity of FLASH Radiotherapy in Cats with Squamous Cell Carcinoma of the Nasal Planum and in Mini Pigs. PMID 35421221 · Clin Cancer Res · 2022-Sep-01 The study is a randomized phase III trial with primary results, but it is not eligible because it is an animal study (cats), the intervention is not drug-containing, and the endpoints are not time-to-event efficacy outcomes.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis. PMID 38319812 · NEJM Evid · 2022-Sep 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
SENSITIVITY ANALYSIS FOR EVALUATING PRINCIPAL SURROGATE ENDPOINTS RELAXING THE EQUAL EARLY CLINICAL RISK ASSUMPTION. PMID 37008748 · Ann Appl Stat · 2022-Sep 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Neoadjuvant immunotherapy in non-small cell lung cancer: a narrative review on mechanisms, efficacy and safety. PMID 36245597 · J Thorac Dis · 2022-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma. PMID 36199496 · J Adv Pract Oncol · 2022-Sep 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Growth analysis among adolescents with moderate-to-severe atopic dermatitis receiving upadacitinib in combination with topical corticosteroids in Japan: A case study series from a phase 3, randomized, controlled trial (Rising Up). PMID 36185549 · World Allergy Organ J · 2022-Sep 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. PMID 36175782 · Neurotherapeutics · 2022-Sep 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial PIPAC VEROne. PMID 36159218 · Pleura Peritoneum · 2022-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Keeping up the 'race pace' in a patient with nonuterine leiomyosarcoma. PMID 36154278 · Future Oncol · 2022-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The DEXA-SEPSIS study protocol: a phase II randomized double-blinded controlled trial of the effect of early dexamethasone in high-risk sepsis patients. PMID 36116775 · Clin Exp Emerg Med · 2022-Sep 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer. PMID 36088050 · Taiwan J Obstet Gynecol · 2022-Sep 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. PMID 36000541 · Future Oncol · 2022-Sep The record is a clinical trial protocol describing the design of the HERIZON-GEA-01 study. It does not report any trial results, including primary or secondary time-to-event efficacy endpoints. Therefore, it is excluded as a protocol without results.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer. PMID 35969032 · Future Oncol · 2022-Sep 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. PMID 35964471 · Eur J Cancer · 2022-Sep 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis. PMID 35964470 · Eur J Cancer · 2022-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer. PMID 35950566 · Future Oncol · 2022-Sep 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110). PMID 35940054 · Eur J Cancer · 2022-Sep 命中用户提供的消化道肿瘤阳性参考集。
H S B
严格 v3 独有 eligiblepositive_reference needs_review 0 Figure · 0 Panel · risk not_assessed
Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US. PMID 35930188 · Diabetes Ther · 2022-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. PMID 35924546 · Future Oncol · 2022-Sep The record describes a Phase III randomized controlled trial in oncology (essential thrombocythemia, a myeloproliferative neoplasm) with a drug intervention. However, it is explicitly a 'Clinical Trial Protocol' (publication type) and the abstract confirms it 'will evaluate' outcomes, indicating no final results are presented. No time-to-event endpoint (OS, PFS, etc.) is described in the provided text. Therefore, it is excluded as a protocol-without-results and lacks the required efficacy endpoint signal.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation. PMID 35917057 · Dermatol Ther (Heidelb) · 2022-Sep 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Protocol for the Vitamin D Oral Replacement in Asthma (VDORA) study. PMID 35907490 · Contemp Clin Trials · 2022-Sep 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A review of patient-reported outcome assessments in registration trials of FDA-approved new oncology drugs (2014-2018). PMID 35901962 · Contemp Clin Trials · 2022-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial. PMID 35879941 · EClinicalMedicine · 2022-Sep 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Microsatellite instability and sex differences in resectable gastric cancer - A pooled analysis of three European cohorts. PMID 35863110 · Eur J Cancer · 2022-Sep 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Availability of results of academic randomized trials involving cooperative groups in oncology in France: A systematic search of clinical trial registries. PMID 35779787 · J Cancer Policy · 2022-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -